Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

LORATADINE

All products: not a benefit

Other products in the same Health Canada class (R06A, R06AX) — coverage varies; not interchangeable

  • Bilastine (Jamp Bilastine Oral Solution): not a benefit
  • Rupatadine (Rupall): not a benefit
  • Cetirizine (Reactine): not a benefit

Claritin · DIN 00782696 · 10mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Claritin · DIN 00782696 Manufacturer: Schering-Plough Canada Inc.; listing date 2007-12-19 Health Canada: Marketed since 2020-02-27 · brand CLARITIN ALLERGY · ATC R06AX13 LORATADINE · form Tablet · route Oral · ingredients LORATADINE 10 MG · company Bayer inc · schedule Non-prescription drugs
Check this DIN again · Health Canada product record

Claritin: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10533 · Verify on the e-Formulary ↗ (DIN 00782696)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 00782696). DIN 00782696: Claritin Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 040000061; group id 3; item number 0005; lccId None; manufacturer id SCP Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00782696 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10533
Interchangeable products
Apo-Loratadine · DIN 02243880 · $0.6267
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00782696
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (04:00 ANTIHISTAMINES) and how they are covered

Matched class: 04:00 ANTIHISTAMINES

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. No displayed product is listed as a general benefit in this extract. Check its listing requirements below. 04:00 ANTIHISTAMINES

BILASTINE

· 12 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2.5mg/mL, 20mg · Oral Sol, Tab

RUPATADINE

· 4 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 10mg · Tab

CETIRIZINE HYDROCHLORIDE

· 21 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 10mg, 20mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 04:00
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE CLARITIN ALLERGY (Loratadine Tablets, USP, 10 mg), CLARITIN Rapid Dissolve (Loratadine Orally Disintegrating Tablets USP, 10 mg) and CLARITIN Rapid Dissolve (Loratadine Orally Disintegrating Tablets USP, 5 mg) are indicated for:  the relief of symptoms associated with seasonal and perennial allergic rhinitis, such as sneezing, nasal discharge and itching, and ocular itching and burning.  the relief of symptoms and signs of chronic urticaria and other allergic dermatologic disorders. Clinical studies to date support treatment for up to six months, thus medical recommendation is advised for longer-term use. CLARITIN Rapid Dissolve should be taken on an empty stomach. CLARITIN KIDS (Loratadine Oral Solution USP, 1 mg/mL) is indicated for:  the relief of symptoms associated with seasonal allergic rhinitis, such as sneezing, nasal discharge and itching, and ocular itching and burning.  the relief of symptoms and signs of chronic urticaria and other allergic dermatologic disorders. CLARITIN ALLERGY, CLARITIN RAPID DISSOLVE, CLARITIN KIDS RAPID DISSOLVE & CLARITIN KIDS … https://pdf.hres.ca/dpd_pm/00058978.PDF PM date: not printed or not captured Source product: CLARITIN ALLERGY; DIN 00782696; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Claritin: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026